Gilead/Roche Tamiflu Has Two-Thirds Of Flu Market, Gilead Tells BIO
Executive Summary
Tamiflu is garnering about two-thirds of U.S. neuraminidase inhibitor prescriptions as the 1999-2000 flu season winds down, Gilead CEO John Martin, PhD, said Feb. 16 at the Biotechnology Industry Organization CEO and Investor Conference in New York City.